Abstract Library

#4646 Dysregulated miRNA in patients with GEP-NEN and potential role as circulating biomarker

Introduction: Neuroendocrine neoplasms (NENs) are a class of rare and molecularly extremely heterogeneous tumours. NENs arise predominantly in the gastrointestinal (GEP) and pulmonary tracts but can also involve thyroid and breast. NENs often present with non-specific symptoms and lack early specific biomarkers, leading to frequent metastatic diagnoses and primary site challenges.

Conference:

Presenting Author:

Authors: Di Mauro A, Clemente O, Cannella L, Della Vittoria G, Neri G,

Keywords: neuroendocrine tumour, miRNome profiling, biomarker, gep-net, molecular biology,

#4625 Efficacy and safety of capecitabine-temozolomide (CAPTEM) regimen in patients with neuroendocrine neoplasms – A systematic review and experience from NETwerk, a Belgian ENETS Center of Excellence

Introduction: Current treatment guidelines remain inconclusive due to scarcity of data regarding the optimal systemic treatment for metastatic gastroenteropancreatic (GEP) neuroendocrine tumours (NET) grade 3 and aggressive GEP-NET grade 2. Similarly, for metastatic pulmonary typical (TC) and atypical carcinoids (AC), the indication for chemotherapy is unclear. Recent evidence highlights a promising role for CAPTEM, combining temozolomide (TEM) with capecitabine (CAP), showing encouraging antitumoural activity and safety profiles for these indications.

Conference:

Presenting Author: Chhajlani S

Authors: Chhajlani S, Lambrechts C, Islam O, de Weerdt C, Verbruggen L,

Keywords: capecitabine, temozolomide, CAPTEM, GEP-NET, pulmonary NEN, safety, efficacy, systematic review,

#4568 Investigating the dual role of SNW1 in splicing and transcription to understand pancreatic neuroendocrine tumour progression

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are classified into grades (G1-G3) based on mitotic rate, with higher grades exhibiting increased dedifferentiation and invasiveness. Despite the clinical significance of PanNETs progression, the underlying mechanisms remain largely unexplored. We have previously reported that altered alternative splicing plays an essential role in PanNETs progression, where SNW1, a key regulator of splicing and transcription, was found to be overexpressed in tumour tissue, correlating with higher grade and recurrence risk.

Conference:

Presenting Author: González-Pérez C

Authors: González-Pérez C, Simón-Lesnyak M, Blázquez-Encinas R, García Vioque V, Moreno Montilla M,

Keywords: pancreas, neuroendocrine tumour, progression, SNW1, splicing,

#4546 Epigenetic exploration of mesenteric fibrosis indicates epigenetic disruption of DAXX is driving metastatic potential in small intestinal neuroendocrine tumours

Introduction: Up to 50% of patients diagnosed with small intestinal neuroendocrine tumours (SI-NETs) are affected by mesenteric fibrosis (MF) which has significant pathological effects and impacts patient mortality.

Conference:

Presenting Author: Webster A

Authors: Webster A, Martins M, Hodgetts H, Feelders R, Hofland L,

Keywords: DNA methylation, SI-NET, Mesenteric fibrosis, Epigenetics, Gene regulation, DAXX,

#4518 Efficacy and safety of cabozantinib (CABO) for advanced Grade 3 (G3) neuroendocrine tumours (NETs) after progression on prior therapy: Subgroup analysis of the phase III CABINET trial (Alliance A021602)

Introduction: Well-differentiated G3 NETs have been described as a distinct category recently, and randomised data regarding efficacy of therapy are scarce. In the phase 3 CABINET trial (NCT03375320), CABO significantly prolonged progression-free survival (PFS) compared with placebo (PB) in patients (pts) with advanced, previously treated, progressive well-differentiated extra-pancreatic NETs (epNETs) and pancreatic NETs (pNETs) of all grades (Chan et al., NEJM, 2024).

Conference:

Presenting Author: Strosberg J

Authors: Strosberg J, Zemla T, Geyer S, Pulsipher S, Behr S,

Keywords: cabozantinib, grade 3 neuroendocrine tumour, pancreatic neuroendocrine tumour, extra-pancreatic neuroendocrine tumour,